Johnson & Johnson (NYSE: JNJ) Stock Competitors & Peer Comparison

Johnson & Johnson (NYSE: JNJ) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, JNJ stands at 650.6B. In comparison, LLY has a market cap of 1.1T. Regarding current trading prices, JNJ is priced at $269.99 on the NYSE, while LLY trades at $1,152.22.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

JNJ currently has a P/E ratio of 25.16, whereas LLY's P/E ratio is 36.61. In terms of profitability, JNJ's ROE is +0.26%, compared to LLY's ROE of +0.93%. Regarding short-term risk, JNJ is more volatile compared to LLY. This indicates higher risk in terms of short-term price fluctuations for JNJ.Check LLY's competition here

Johnson & Johnson (NYSE: JNJ) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, JNJ stands at 650.6B. In comparison, ABBV has a market cap of 466.1B. Regarding current trading prices, JNJ is priced at $269.99 on the NYSE, while ABBV trades at $263.78.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

JNJ currently has a P/E ratio of 25.16, whereas ABBV's P/E ratio is 25.89. In terms of profitability, JNJ's ROE is +0.26%, compared to ABBV's ROE of -1.36%. Regarding short-term risk, JNJ is more volatile compared to ABBV. This indicates higher risk in terms of short-term price fluctuations for JNJ.Check ABBV's competition here

Johnson & Johnson (NYSE: JNJ) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, JNJ stands at 650.6B. In comparison, MRK has a market cap of 362.5B. Regarding current trading prices, JNJ is priced at $269.99 on the NYSE, while MRK trades at $146.76.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

JNJ currently has a P/E ratio of 25.16, whereas MRK's P/E ratio is 45.72. In terms of profitability, JNJ's ROE is +0.26%, compared to MRK's ROE of +0.07%. Regarding short-term risk, JNJ is more volatile compared to MRK. This indicates higher risk in terms of short-term price fluctuations for JNJ.Check MRK's competition here

Johnson & Johnson (NYSE: JNJ) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, JNJ stands at 650.6B. In comparison, NVS has a market cap of 266.8B. Regarding current trading prices, JNJ is priced at $269.99 on the NYSE, while NVS trades at $140.37.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

JNJ currently has a P/E ratio of 25.16, whereas NVS's P/E ratio is 16.15. In terms of profitability, JNJ's ROE is +0.26%, compared to NVS's ROE of +0.30%. Regarding short-term risk, JNJ is more volatile compared to NVS. This indicates higher risk in terms of short-term price fluctuations for JNJ.Check NVS's competition here

Johnson & Johnson (NYSE: JNJ) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, JNJ stands at 650.6B. In comparison, AZN has a market cap of 257.5B. Regarding current trading prices, JNJ is priced at $269.99 on the NYSE, while AZN trades at $166.08.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

JNJ currently has a P/E ratio of 25.16, whereas AZN's P/E ratio is 17.93. In terms of profitability, JNJ's ROE is +0.26%, compared to AZN's ROE of +0.22%. Regarding short-term risk, JNJ is more volatile compared to AZN. This indicates higher risk in terms of short-term price fluctuations for JNJ.Check AZN's competition here

Johnson & Johnson (NYSE: JNJ) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, JNJ stands at 650.6B. In comparison, AMGN has a market cap of 205B. Regarding current trading prices, JNJ is priced at $269.99 on the NYSE, while AMGN trades at $385.65.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

JNJ currently has a P/E ratio of 25.16, whereas AMGN's P/E ratio is 16.98. In terms of profitability, JNJ's ROE is +0.26%, compared to AMGN's ROE of +0.89%. Regarding short-term risk, JNJ is less volatile compared to AMGN. This indicates lower risk in terms of short-term price fluctuations for JNJ.Check AMGN's competition here

Johnson & Johnson (NYSE: JNJ) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, JNJ stands at 650.6B. In comparison, NVO has a market cap of 192B. Regarding current trading prices, JNJ is priced at $269.99 on the NYSE, while NVO trades at $43.24.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

JNJ currently has a P/E ratio of 25.16, whereas NVO's P/E ratio is 10.76. In terms of profitability, JNJ's ROE is +0.26%, compared to NVO's ROE of +0.59%. Regarding short-term risk, JNJ is more volatile compared to NVO. This indicates higher risk in terms of short-term price fluctuations for JNJ.Check NVO's competition here

Johnson & Johnson (NYSE: JNJ) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, JNJ stands at 650.6B. In comparison, GILD has a market cap of 186.4B. Regarding current trading prices, JNJ is priced at $269.99 on the NYSE, while GILD trades at $150.11.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

JNJ currently has a P/E ratio of 25.16, whereas GILD's P/E ratio is -384.90. In terms of profitability, JNJ's ROE is +0.26%, compared to GILD's ROE of -0.16%. Regarding short-term risk, JNJ is less volatile compared to GILD. This indicates lower risk in terms of short-term price fluctuations for JNJ.Check GILD's competition here

Johnson & Johnson (NYSE: JNJ) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, JNJ stands at 650.6B. In comparison, PFE has a market cap of 157.3B. Regarding current trading prices, JNJ is priced at $269.99 on the NYSE, while PFE trades at $27.66.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

JNJ currently has a P/E ratio of 25.16, whereas PFE's P/E ratio is 9.05. In terms of profitability, JNJ's ROE is +0.26%, compared to PFE's ROE of +0.05%. Regarding short-term risk, JNJ is more volatile compared to PFE. This indicates higher risk in terms of short-term price fluctuations for JNJ.Check PFE's competition here

Johnson & Johnson (NYSE: JNJ) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, JNJ stands at 650.6B. In comparison, BMY has a market cap of 128.8B. Regarding current trading prices, JNJ is priced at $269.99 on the NYSE, while BMY trades at $63.06.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

JNJ currently has a P/E ratio of 25.16, whereas BMY's P/E ratio is 10.63. In terms of profitability, JNJ's ROE is +0.26%, compared to BMY's ROE of +0.47%. Regarding short-term risk, JNJ is more volatile compared to BMY. This indicates higher risk in terms of short-term price fluctuations for JNJ.Check BMY's competition here

Johnson & Johnson (NYSE: JNJ) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, JNJ stands at 650.6B. In comparison, SNY has a market cap of 102B. Regarding current trading prices, JNJ is priced at $269.99 on the NYSE, while SNY trades at $42.48.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

JNJ currently has a P/E ratio of 25.16, whereas SNY's P/E ratio is 9.25. In terms of profitability, JNJ's ROE is +0.26%, compared to SNY's ROE of +0.06%. Regarding short-term risk, JNJ is more volatile compared to SNY. This indicates higher risk in terms of short-term price fluctuations for JNJ.Check SNY's competition here

Johnson & Johnson (NYSE: JNJ) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, JNJ stands at 650.6B. In comparison, GSK has a market cap of 100.6B. Regarding current trading prices, JNJ is priced at $269.99 on the NYSE, while GSK trades at $50.22.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

JNJ currently has a P/E ratio of 25.16, whereas GSK's P/E ratio is 10.85. In terms of profitability, JNJ's ROE is +0.26%, compared to GSK's ROE of +0.24%. Regarding short-term risk, JNJ is more volatile compared to GSK. This indicates higher risk in terms of short-term price fluctuations for JNJ.Check GSK's competition here

Johnson & Johnson (NYSE: JNJ) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, JNJ stands at 650.6B. In comparison, BIIB has a market cap of 31.8B. Regarding current trading prices, JNJ is priced at $269.99 on the NYSE, while BIIB trades at $215.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

JNJ currently has a P/E ratio of 25.16, whereas BIIB's P/E ratio is 13.60. In terms of profitability, JNJ's ROE is +0.26%, compared to BIIB's ROE of +0.05%. Regarding short-term risk, JNJ is less volatile compared to BIIB. This indicates lower risk in terms of short-term price fluctuations for JNJ.Check BIIB's competition here

Johnson & Johnson (NYSE: JNJ) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, JNJ stands at 650.6B. In comparison, HZNP has a market cap of 26.6B. Regarding current trading prices, JNJ is priced at $269.99 on the NYSE, while HZNP trades at $116.30.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

JNJ currently has a P/E ratio of 25.16, whereas HZNP's P/E ratio is 61.86. In terms of profitability, JNJ's ROE is +0.26%, compared to HZNP's ROE of +0.11%. Regarding short-term risk, JNJ is more volatile compared to HZNP. This indicates higher risk in terms of short-term price fluctuations for JNJ.Check HZNP's competition here

Johnson & Johnson (NYSE: JNJ) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, JNJ stands at 650.6B. In comparison, GRFS has a market cap of 6.2B. Regarding current trading prices, JNJ is priced at $269.99 on the NYSE, while GRFS trades at $7.31.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

JNJ currently has a P/E ratio of 25.16, whereas GRFS's P/E ratio is 8.40. In terms of profitability, JNJ's ROE is +0.26%, compared to GRFS's ROE of +0.08%. Regarding short-term risk, JNJ is more volatile compared to GRFS. This indicates higher risk in terms of short-term price fluctuations for JNJ.Check GRFS's competition here

Johnson & Johnson (NYSE: JNJ) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, JNJ stands at 650.6B. In comparison, OGN has a market cap of 3.6B. Regarding current trading prices, JNJ is priced at $269.99 on the NYSE, while OGN trades at $13.68.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

JNJ currently has a P/E ratio of 25.16, whereas OGN's P/E ratio is 4.09. In terms of profitability, JNJ's ROE is +0.26%, compared to OGN's ROE of +0.23%. Regarding short-term risk, JNJ is more volatile compared to OGN. This indicates higher risk in terms of short-term price fluctuations for JNJ.Check OGN's competition here

Johnson & Johnson (NYSE: JNJ) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, JNJ stands at 650.6B. In comparison, AMRN has a market cap of 286.9M. Regarding current trading prices, JNJ is priced at $269.99 on the NYSE, while AMRN trades at $13.63.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

JNJ currently has a P/E ratio of 25.16, whereas AMRN's P/E ratio is -138.70. In terms of profitability, JNJ's ROE is +0.26%, compared to AMRN's ROE of -0.06%. Regarding short-term risk, JNJ is less volatile compared to AMRN. This indicates lower risk in terms of short-term price fluctuations for JNJ.Check AMRN's competition here

Johnson & Johnson (NYSE: JNJ) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, JNJ stands at 650.6B. In comparison, SCLX has a market cap of 42.8M. Regarding current trading prices, JNJ is priced at $269.99 on the NYSE, while SCLX trades at $5.04.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

JNJ currently has a P/E ratio of 25.16, whereas SCLX's P/E ratio is -0.13. In terms of profitability, JNJ's ROE is +0.26%, compared to SCLX's ROE of +1.90%. Regarding short-term risk, JNJ is less volatile compared to SCLX. This indicates lower risk in terms of short-term price fluctuations for JNJ.Check SCLX's competition here

Johnson & Johnson (NYSE: JNJ) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, JNJ stands at 650.6B. In comparison, MIRA has a market cap of 34.2M. Regarding current trading prices, JNJ is priced at $269.99 on the NYSE, while MIRA trades at $0.83.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

JNJ currently has a P/E ratio of 25.16, whereas MIRA's P/E ratio is -0.56. In terms of profitability, JNJ's ROE is +0.26%, compared to MIRA's ROE of -1.07%. Regarding short-term risk, JNJ is less volatile compared to MIRA. This indicates lower risk in terms of short-term price fluctuations for JNJ.Check MIRA's competition here

Johnson & Johnson (NYSE: JNJ) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, JNJ stands at 650.6B. In comparison, SCLXW has a market cap of 33.6M. Regarding current trading prices, JNJ is priced at $269.99 on the NYSE, while SCLXW trades at $0.10.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

JNJ currently has a P/E ratio of 25.16, whereas SCLXW's P/E ratio is N/A. In terms of profitability, JNJ's ROE is +0.26%, compared to SCLXW's ROE of +1.90%. Regarding short-term risk, JNJ is less volatile compared to SCLXW. This indicates lower risk in terms of short-term price fluctuations for JNJ.Check SCLXW's competition here

Johnson & Johnson (NYSE: JNJ) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, JNJ stands at 650.6B. In comparison, BDSIW has a market cap of 0. Regarding current trading prices, JNJ is priced at $269.99 on the NYSE, while BDSIW trades at $0.04.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

JNJ currently has a P/E ratio of 25.16, whereas BDSIW's P/E ratio is -0.43. In terms of profitability, JNJ's ROE is +0.26%, compared to BDSIW's ROE of +0.57%. Regarding short-term risk, JNJ is less volatile compared to BDSIW. This indicates lower risk in terms of short-term price fluctuations for JNJ.Check BDSIW's competition here

Johnson & Johnson (NYSE: JNJ) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, JNJ stands at 650.6B. In comparison, CRXT has a market cap of 0. Regarding current trading prices, JNJ is priced at $269.99 on the NYSE, while CRXT trades at $0.05.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

JNJ currently has a P/E ratio of 25.16, whereas CRXT's P/E ratio is -0.02. In terms of profitability, JNJ's ROE is +0.26%, compared to CRXT's ROE of -4.63%. Regarding short-term risk, JNJ is less volatile compared to CRXT. This indicates lower risk in terms of short-term price fluctuations for JNJ.Check CRXT's competition here